Could less chemo mean better quality of life for bladder cancer patients?
NCT ID NCT06892860
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares 3 versus 6 cycles of platinum-based chemotherapy followed by the immunotherapy drug avelumab in 320 people with advanced bladder cancer. The goal is to see if fewer chemo cycles improve quality of life without harming cancer control. Participants receive either 3 or 6 cycles of chemo, then avelumab every 2 weeks for up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab (a cancer immunotherapy drug) plus platinum-based chemotherapy (gemcitabine plus cisplatin or carboplatin)
What this could lead to
If successful, this could show that shorter chemotherapy (3 cycles) before immunotherapy is just as effective and improves quality of life for people with advanced bladder cancer.
What could go wrong
This is a phase 2 trial, so results are preliminary. The shorter chemo might not control the cancer as well, and side effects from avelumab (like immune reactions) are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Adknoma
ENROLLING_BY_INVITATIONMadrid, Spain
-
Barts Health NHS Trust
RECRUITINGLondon, United Kingdom
Contact
-
Unicancer
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••